Tumori Journal Abstract Book - October 2020 - 49

C - Gastrointestinal (non-Colorectal) Cancers	
evaluated for: MMR, EBV, and PD-L1 status. HER-2 status was also tested according to guidelines. Pts treated
with at least one line of chemotherapy (1L) and having at
least one biomarker tested were eligible. Chi-square and
t-student test were used to assess the association between
categorial and continue variables of interest.
Results: A total of 87 AGC were included in the analysis
The median age was 66 years and 62% (n=54) were males.
83% (n=72) presented with novo AGC and 84% (n=73)
had an ECOG PS of 0-1. 18/87 (21%) had HER-2 positive
AGC, all with pMMR status. dMMR was detected in 6/87
(6.8%) pts, showing an older median age at diagnosis (68
vs 64 years; p=0.04). While all dMMR pts had nodal
involvement, no differences in number of metastatic sites
nor in biochemical parameters were recorded (p=0.85)
between dMMR and pMMR pts. All dMMR pts received
1L without achieving an objective response and 2/6 (33%)
experienced early progression. 3/6 (50%) were treated
with ICI in later lines and 2/3 (67%) achieved a durable
and still ongoing benefit with a median duration of
response of 10.5 months. EBV-positivity was detected in
4/87 (4.5%) of pts and all of them obtained a clinical benefit with chemotherapy (3 PR and 1 SD). PD-L1 CPS was
available for 29/87 pts (33%), 65% (n=19) displaying CPS
⩾ 1 and 19% (n=5) CPS ⩾ 10. No pts in both EBV- and
PD-L1 positive group were treated with ICI.
Conclusions: We reported one of the first real-world characterization of MMR, EBV and PD-L1 status in a wellannotated cohort of AGC receiving systemic treatment.
While dMMR tumours confirmed to benefit from ICI and
not from chemotherapy, EBV-positive AGC achieved a
significant disease control with cytotoxics. Although limited by its small sample size, this study provided a piece of
evidence on the clinical utility and feasibility of MMR,
EBV and PD-L1 testing in daily practice.

C08
THE IMPACT OF CT-BASED BODY
COMPOSITION PARAMETERS ON
SURVIVAL OUTCOMES IN WESTERN
PATIENTS (PTS) WITH RESECTED
GASTRIC AND GASTROESOPHAGEAL
JUNCTION ADENOCARCINOMA
(GEA) TREATED WITH ADJUVANT
CHEMOTHERAPY
Santini C.1, Salati M.1, Pecchi A.1, Prampolini F.1, Kaleci S.2, Canino
F.1, Benatti S.1, Casadei Gardini A.1, Gelsomino F.1, Luppi G.1,
Torricelli P.2, Dominici M.2, Spallanzani A.1
1
Azienda Ospedaliero-Universitaria di Modena, Modena; 2Università degli
Studi di Modena e Reggio Emilia, Modena

Background: Sarcopenia is a multifactorial syndrome
defined by progressive and generalized loss of skeletal

49
muscle mass, reduction of strength and physical performance which has been increasingly correlating with
impaired cancer patient outcomes. High accuracy and
reproducible results make CT one of the gold standard for
body composition measurement. We aimed at assessing
the impact of CT-based body composition parameters on
the survival outcomes of resected GEA.
Methods: cT3-T4 and/or N-positive GEA pts undergoing
curative-intent resection followed by adjuvant chemotherapy
at our Institution between 2008-2018 were eligible.
Presurgical clinicopathologic, biochemical, and antropometric data were retrospectively retrieved, while body composition parameters and its deltas were derived by CT scan using
GE Healthcare AW VolumeShare 7 software. Univariate and
multivariate analyses for DFS and OS were performed.
Results: A total of 107 pts were included in the analysis.
Median age was 66.1 years (range 20-85), 61 (57%) were
males. 45 pts (42.1%) had stage II, while 62 pts (57.9%)
had stage III. Mean preoperative BMI was 23.9 kg/m2. CT
scans were performed presurgically and from 4 to 15
months after resection. In the whole population, the 3-year
DFS and OS were 48% and 49%, respectively. Out of 27
tested covariates, baseline IntraMuscular Adipose tissue
Content (IMAC), together with ECOG PS and disease
stage, was significantly associated with DFS (HR 1,97;
p=0.03) and OS (HR 1,77; p=0.04) at the multivariate
analysis. Specifically, pts with high baseline IMAC (⩾
-0.42) had a shorter 3-year DFS (35% vs 62%, p<0,018)
and 5-year OS (32% vs 55%, p=0,037).
Conclusions: We showed for the first time that presurgical
IMAC, which reflects the quality of skeletal muscle, was
an independent predictor of survival in resected GEA. This
easy-to-calculate and largely available CT-derived parameter, may identify high-risk patients in need for a prompt
and tailored nutritional intervention aimed at improving
patients' outcome.

C09
Real-life clinical data of
cabozantinib for unresectable
hepatocellular carcinoma
Tovoli F.1, Dadduzio V.2, De Lorenzo S.3, Garajovà I.4, Marra F.5,
Trevisani F.6, Pini S.7, Granito A.1, Zagonel V.2, Brandi G.3, Piscaglia F.1
1
University of Bologna, Department of Medical and Surgical Sciences, Unit of
Internal Medicine, Bologna; 2Istituto Oncologico Veneto, Padova; 3University
of Bologna, Department of Experimental, Diagnostic and Specialty Medicine,
Unit of Oncology, Bologna; 4AOU Parma, Oncology Unit, Parma; 5University
of Florence, Firenze; 6University of Bologna, Department of Medical and
Surgical Sciences, Unit of Semiotics, Bologna; 7AUSL Romagna, Rimini

Background: Cabozantinib (CABO) has been approved
by the European Medicine Agency (EMA) as a second or
third-line therapy for hepatocellular carcinoma (HCC) previously treated with sorafenib. CABO is also being tested
Tumori Journal Abstract Book - October 2020

Table of Contents for the Digital Edition of Tumori Journal Abstract Book - October 2020
